Abbott Laboratories kicked off the trading day on 08/14/19 with a price decrease of -3.40%, equivalent to -$2.95 relative change for the day. Taking a more long-term approach, ABT had a 52-week range of $63.07 to $88.76. At the time of this article’s publishing, this stock is trading at $83.94 after starting the trading session at $85.88. Moving on, the stock has demonstrated a 52-week change amounting to 33.64, alongside an S&P500 52-Week Change of 25.32. At the time of writing, this stock’s 50-day Moving Average stands at $84.78, while the 200-day Moving Average of this stock is currently $76.73.
Currently, this company’s share volume is sitting at $4,082,237, but has maintained average daily volume of $5.14M. This stock has generated an average Year to Date volume of $5.65 million, alongside an average 20-day volume of $5.11 million. This publicly-traded company’s shares outstanding now amounts to $1.77 billion, simultaneously with a float of $1.75 billion. The organization now has a market capitalization sitting at $148.48 billion.
Abbott Laboratories(ABT) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Abbott Laboratories’s current insider ownership accounts for 0.70%, in contrast to 76.00% institutional ownership. According to the most recent latest insider trade that took place on Aug 09 this organization’s Senior Vice President exercised an option 23,008 at the rate of 50.72, making the entire transaction hit 1,166,966 in total value, affecting insider ownership by 104,228. Preceding that transaction, on Aug 09 Company’s Senior Vice President exercised an option 40,000 at a price of 34.94, making the whole transaction’s value amount to 1,397,600. This particular insider is now the holder of 178,991 in total.
If we take a glance at the Ownership summary of Abbott Laboratories’s stock, 2,084 Institutional holders make up 74.36% of its total stock ownership. All together, they are the legal holders of 1,314,171,633 shares, which are valued at about $114,188,373,191 in total. If we focus on the top 3 stockholders for this publicly-traded organization, VANGUARD GROUP INC owns 146.07 million shares, with BLACKROCK INC. in 2nd place owning 126.53 million shares and CAPITAL RESEARCH GLOBAL INVESTORS in third place with total ownership of 115.57 million shares.
Abbott Laboratories (ABT) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on Jun-19, the organization reported $0.82 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at $0.80) by $0.02.
The corporation racked up revenue of $7,535.00million for the previous financial quarter, compared to the mean analyst estimate of $7,473.78 million. This company achieved a net margin of 9.36 while generating a return on equity of 9.37. Abbott Laboratories’s full-quarter revenue increased by 2.73%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.84 per share during the current fiscal year.
Abbott Laboratories’s EPS increase for this current 12-month fiscal period is 34.30%, and is forecasted to reach 11.53% in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by 11.81% through the next 5 years, which can be compared against the 2.00% growth it accomplished over the previous five years trading on the market.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Abbott Laboratories, this organization’s Quick Ratio in the last reported quarter now stands at 1.20. The company has managed to achieve an average true range (ATR) of 1.86. Alongside those, its PE Ratio stands at $51.06, and its Beta score is 1.13.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.80 for this organization. Similarly, its price to free cash flow for trailing twelve months is now 75.22. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 4.69, whereas its price to cash per share for the last quarter landed at 1.91.
In the same vein, ABT’s Diluted EPS (Earnings per Share) trailing twelve month was posted at 1.64, a figure that is expected to reach 0.84 in the next reported quarter, and analysts expect it will be 11.53% at the market close of one year from today’s date.